EP Patent

EP3120851A1 — 4-amino-6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8h)-one for treatment of solid cancers

Assigned to Institut Quimic de Sarria CETS Fundacio Privada · Expires 2017-01-25 · 9y expired

What this patent protects

The present invention relates to 4-amino-6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)-pyrido[2,3- d ]pyrimidin-7(8 H )-one of formula (1) for use in the treatment and/or prevention of solid tumors, and combinations comprising said compound and a chemotherapeutic drug.

USPTO Abstract

The present invention relates to 4-amino-6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)-pyrido[2,3- d ]pyrimidin-7(8 H )-one of formula (1) for use in the treatment and/or prevention of solid tumors, and combinations comprising said compound and a chemotherapeutic drug.

Drugs covered by this patent

Patent Metadata

Patent number
EP3120851A1
Jurisdiction
EP
Classification
—
Expires
2017-01-25
Drug substance claim
No
Drug product claim
No
Assignee
Institut Quimic de Sarria CETS Fundacio Privada
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.